

October 12, 2023

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: USFDA Inspection of the Company's material Wholly-owned Subsidiary, Panacea Biotec Pharma Limited's facility at Baddi, Himachal Pradesh, India

Ref.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we hereby inform that the United States Food and Drug Administration ("USFDA") conducted an inspection of the Company's material wholly-owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") at Baddi, Himachal Pradesh, India between October 03, 2023 and October 12, 2023.

At the end of inspection, PBPL was issued a 'FDA Form 483' with nine (9) observations which are related to improvements in existing procedures and are addressable. PBPL will respond to the US FDA within the stipulated time and work closely with US FDA to close the said observations.

We are committed to patient safety and quality and take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards.

We request you to kindly take this on record as per the requirements of SEBI LODR Regulations and oblige.

Thanking you,

Sincerely yours,

For Panacea Biotec Limited

Vinod Goel Group CFO and Head Legal & Company Secretary